These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3406046)

  • 41. Effects of the thromboxane-receptor antagonists AH 23848 and BM 13.177 on human uteroplacental arteries.
    Svane D; Skajaa K; Andersson KE; Forman A
    Obstet Gynecol; 1992 Aug; 80(2):234-40. PubMed ID: 1386150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Modification of the rat uterine response to oestrogen and tamoxifen by thromboxane antagonists.
    Kerr MB; Marshall K; Senior J
    Br J Pharmacol; 1991 Mar; 102(3):742-6. PubMed ID: 1364847
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of trapidil and trapidil derivatives on arachidonic acid and prostaglandin endoperoxide analogue U 46619-induced blood pressure changes in rats.
    Heinroth-Hoffmann I; Hauser A; Taube C; Mest HJ
    Biomed Biochim Acta; 1988; 47(10-11):S145-8. PubMed ID: 3248102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SK&F 88046: inhibition of thromboxane-induced bronchoconstriction in anesthetized dogs.
    Wasserman MA; Malo PE
    Prostaglandins Leukot Med; 1985 Feb; 17(2):213-22. PubMed ID: 2858866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pre- and postjunctional effects of some prostanoids in human isolated vas deferens.
    Holmquist F; Hedlund H; Andersson KE
    Am J Physiol; 1991 Apr; 260(4 Pt 2):R792-7. PubMed ID: 1707245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estradiol potentiates the vasopressor response of the isolated perfused rat lung to the thromboxane mimic U-46619.
    Farhat MY; Ramwell PW
    J Pharmacol Exp Ther; 1992 May; 261(2):686-91. PubMed ID: 1578379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis.
    Thiemermann C; Ney P; Schrör K
    Eur J Pharmacol; 1988 Oct; 155(1-2):57-67. PubMed ID: 2977337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of elevated levels of thromboxane on host response to tumor.
    Waymack JP; Fernandes G; Venkatraman J; Flescher E; Yurt RW; Guzman RF; Mason AD; Pruitt BA
    J Surg Oncol; 1992 Jan; 49(1):3-9. PubMed ID: 1548878
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effects of thromboxane receptor antagonists on oestrogen-induced uterotrophic responses in the spontaneously hypertensive rat.
    Kerr MB; Marshall K; Senior J
    Br J Pharmacol; 1991 Jun; 103(2):1363-6. PubMed ID: 1832065
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth inhibitory effects of thromboxane antagonists on breast cancer cell lines: a preliminary study.
    Marshall K; Lane K; Senior J
    Adv Exp Med Biol; 1997; 400A():455-60. PubMed ID: 9547590
    [No Abstract]   [Full Text] [Related]  

  • 51. A rat model of progressive chronic glomerular sclerosis: the role of thromboxane inhibition.
    Stahl RA; Thaiss F; Wenzel U; Schoeppe W; Helmchen U
    J Am Soc Nephrol; 1992 May; 2(11):1568-77. PubMed ID: 1610977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. SK&F S-106203 inhibits leukotriene C4, leukotriene D4 and leukotriene E4 vasopressor responses in the conscious rat.
    Smith EF; Slivjak MJ; Egan JW; Eckardt RD; Newton JF
    Br J Pharmacol; 1990 Jun; 100(2):195-200. PubMed ID: 2165834
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol.
    Kaplan R; Aynedjian HS; Schlondorff D; Bank N
    J Clin Invest; 1990 Nov; 86(5):1707-14. PubMed ID: 2147028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of the thromboxane receptor antagonist, BM 13.505, on the sequelae of endotoxemia in the conscious rat.
    Smith EF; Jugus M; Kinter LB
    Eicosanoids; 1988; 1(1):27-33. PubMed ID: 3078574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505.
    Smith EF; Griswold DE; Egan JW; Hillegass LM; DiMartino MJ
    J Cardiovasc Pharmacol; 1989 May; 13(5):715-22. PubMed ID: 2472519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanism of antagonism of thromboxane receptors in vascular smooth muscle.
    Yanagisawa A; Smith JA; Brezinski ME; Lefer AM
    Eur J Pharmacol; 1987 Jan; 133(1):89-96. PubMed ID: 3030773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
    Smith EF; McDonald J
    Pharmacology; 1988; 36(5):340-7. PubMed ID: 3406046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protective effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate against 9,11-dideoxy- 9 alpha, 11 alpha-epoxymethano-prostaglandin F2 alpha-induced sudden death in guinea-pigs and rats.
    Shirakura S; Karasawa A; Kubo K
    Arzneimittelforschung; 1991 Dec; 41(12):1242-5. PubMed ID: 1815523
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.